$ADXS Founder to Present on ADXS-HER2 at World Congress

“I’ve dedicated over 20 years of work to the application of Listeria monocytogenes in targeted tumor-associated antigens,” said Dr. Paterson. “I am thankful for the opportunity to showcase the success of this process in HER2 expressing breast cancers.”

The presentation, which is scheduled to take place during the symposium on “Immunotherapy of Breast Cancer,” will highlight pre-clinical research findings with Advaxis’s Lm Technology(TM) immunotherapy ADXS-HER2 which show promise for limiting tumor growth in HER2 expressing cancers, such as breast cancer. In clinical trials to date in multiple tumor types, Advaxis’s LmTechnology(TM) immunotherapies have been well-tolerated and have demonstrated anti-tumor activity, including prolonged survival, stable disease and, in some cases, complete or partial remission. In addition, preliminary data have demonstrated ADXS-HER2, in combination with palliative radiation, delayed tumor progression and prolonged overall survival in a group of 12 pet dogs with treatment-naive spontaneous canine osteosarcoma.

“We are appreciative of the astounding work Dr. Paterson has done in the area of LmTechnology(TM),” said Daniel J. O’Connor, President and Chief Executive Officer of Advaxis. “Her scientific research has been instrumental in bringing about the first human trial of ADXS-HER2 in locally advanced/metastatic HER2 expressing solid tumors, which is scheduled to commence enrollment this summer.”

Advaxis recently announced the United States Patent and Trademark Office (USPTO) granted a patent expanding Advaxis’s intellectual property portfolio in claiming numerous compositions for the development of ADXS-HER2 in HER2 expressing cancers.

About HER2 Expressing Cancers

Human epidermal growth factor receptor 2 (HER2) is expressed in a percentage of solid tumors such as breast, gastric, bladder, brain, pancreatic, ovarian and osteosarcoma. The American Cancer Society estimates that in 2015 in the United States alone there will be 231,840 new cases of invasive breast cancer; 24,590 new cases of gastric cancer; 74,000 new cases of bladder cancer; 22,850 new cases of brain/spinal cancer; 48,960 new cases of pancreatic cancer; 21,290 new cases of ovarian cancer; and 800 new cases of osteosarcoma. HER2 expression is associated with more aggressive disease, increased risk of relapse and decreased overall survival, and is an important target for immunotherapy.

About ADXS-HER2

ADXS-HER2 is an Lm Technology(TM) immunotherapy product candidate being developed by Advaxis for the targeted treatment of HER2 expressing cancers. ADXS-HER2 received orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of osteosarcoma in May 2014. Advaxis is developing ADXS-HER2 for both human and animal-health, and has seen encouraging data in canine osteosarcoma, which is considered a model for human osteosarcoma. Advaxis licensed ADXS-HER2 and three other immunotherapy constructs to Aratana Therapeutics, Inc. for pet therapeutics.

About Advaxis, Inc.

Located in Princeton, N.J., Advaxis, Inc. is a clinical-stage biotechnology company developing multiple cancer immunotherapies based on its proprietary Lm Technology(TM). The LmTechnology(TM), using bioengineered live attenuated Listeria monocytogenes bacteria, is the only known cancer immunotherapy agent shown in preclinical studies to both generate cancer fighting T-cells directed against a cancer antigen and neutralize Tregs and myeloid-derived suppressor cells (MDSCs), that protect the tumor microenvironment from immunologic attack and contribute to tumor growth. Advaxis’s lead Lm Technology(TM) immunotherapy, ADXS-HPV, targets human papillomavirus (HPV)-associated cancers and is in clinical trials for three indications: Phase 2 in invasive cervical cancer, Phase 1/2 in head and neck cancer, and Phase 1/2 in anal cancer. The U.S. Food and Drug Administration (FDA) has granted Advaxis orphan drug designation for each of these three indications. For additional information on Advaxis, visitwww.advaxis.com and connect on Twitter, LinkedIn, Facebook, YouTube and Google+.

Forward-Looking Statements

This news release contains forward-looking statements, including, but not limited to: statements regarding Advaxis’s ability to develop the next generation of cancer immunotherapies; and the safety and efficacy of Advaxis’s proprietary immunotherapy, ADXS-HPV. These forward-looking statements are subject to a number of risks, including the risk factors set forth from time to time in Advaxis’s SEC filings, including but not limited to its report on Form 10-K for the fiscal year ended October 31, 2014, which is available at https://www.sec.gov. Advaxis undertakes no obligation to publicly release the result of any revision to these forward-looking statements, which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. You are cautioned not to place undue reliance on any forward-looking statements.

CONTACTS:

Company:
Advaxis, Inc.
Greg Mayes, Executive Vice President and COO
mayes@advaxis.com
609.452.9813 ext. 102

Media Contact:
JPA Health Communications
Carolyn Sobczyk
carolyn@jpa.com
402.718.3974